A multicentre PROspective study on the diagnostic value of Steroid profiling in primary ALDOsteronism: The PROSALDO study - PROSALDO

Medizinische Klinik und Poliklinik IV, Klinikum der Universität, LMU München0 sites1,500 target enrollmentJanuary 17, 2020

Overview

Phase: 未知
Intervention: Not specified
Conditions: E26.0
Sponsor: Medizinische Klinik und Poliklinik IV, Klinikum der Universität, LMU München
Enrollment: 1500
Status: Recruiting
Last Updated: last year

No summary available.

Registry

who.int

Start Date

January 17, 2020

End Date

TBD

Last Updated

last year

Study Type

Interventional

Sex

All

Sponsor

Medizinische Klinik und Poliklinik IV, Klinikum der Universität, LMU München

•Male and female adult patients (18\-70 yr) with hypertension who are suspected to have PA and in whom other causes of secondary hypertension have been excluded according to standard clinical criteria
•All subjects must have read, understood and signed the informed consent form before inclusion into the study protocol

•Patients with other forms of secondary hypertension
•Subjects who need medications that may interfere with or invalidate outcome parameters (e.g., steroids, oral contraceptives)
•Patients with low or low\-normal aldosterone (basal aldosterone \<6\.1 ng/dl) (\<170 pmol/l)
•Pregnancy
•Patients with impaired mental capacity that precludes informed consent
•Patients at risk of allergic reaction to contrast media
•Unsuitability for or objection to undergo AVS, CT or adrenal surgery
•Severe or terminal co\-morbidity which seriously interferes with possible treatment or health related quality of life